TeleHD: Establishing feasibility, validity, and value of telemedicine in Huntington’s disease
Main Article Content
Abstract
Objective: To demonstrate the feasibility of conducting telemedicine visits, establish the validity and reliability of tele-administered motor/non-motor assessments, and determine the satisfaction of virtual visits for individuals with Huntington disease (HD).
Background: Telemedicine has become a prevalent method for patients to interact with their healthcare providers. Patients with HD often cite time and travel burden as significant barriers to receive care in HDSA centers of excellence. TeleHD studied the applicability of telemedicine in a specialized HD clinic at a large urban center.
Methods: Individuals aged 18 to 70 with genetically confirmed HD, MoCA score >26, and a smartphone or computer were enrolled. Participants completed 2 pairs of in-person clinic and televisits 1 month apart, completing all 4 visits within a 9-month time frame. Validity of tele-administered composited Unified Huntington's Disease Rating Scale (UHDRS) component of Total Motor Score (TMS), Total Functional Capacity (TFC) Score, Symbol Digit Modalities Test (SMT), and Stroop Color and Word Test (SCWT) was assessed by measuring the strength of the association with clinic-administered scales using Pearson correlation coefficients. Intraclass correlation coefficients (ICC) were calculated to assess cross-sectional reliability and agreement between in-person and tele-administered scales. The value of televisits was assessed with a Satisfaction Survey and Resource Utilization Survey.
Results: Thirty-one participants were enrolled. 55% completed all study visits. The cross-sectional correlations for TMS and mTMS at visits 1 and 2 were very high (r=0.95 and r= 0.98), respectively with p<0.01. Similarly high correlations were observed for cognitive tests including TFC, SWRT Word and Color and SDMT (r >0.8, p<0.01), but were lower for Color-Word and Interference. ICCs showed excellent agreement for TMS and mTMS, TFC, SCWT-Color, SCWT-Word, and SDMT. Ten participants completed the satisfaction and utilization surveys.
Conclusions: The results failed to meet the pre-defined measure of feasibility (80% completion of both telehealth visits). Nonetheless, there was evidence of strong validity and reliability of tele-administration of multiple assessment scales, including administered modified TMS, TFC scale, and cognitive assessments SWCT and SDMT. Respondents to the satisfaction and utilization surveys (N=10) were either satisfied or very satisfied with televisit convenience, comfort, and care.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Houston E, Kennedy AG, O'Malley D, Rabinowitz T, Rose GL, Boyd J. Telemedicine in Neurology: A Scoping Review of Key Outcomes in Movement Disorders. Telemed J E Health. 2022;28(3):295-308.
3. Abdolahi A, Scoglio N, Killoran A, Dorsey A, Biglan K. Potential reliability and validity of a modified version of the Unified Parkinson’s disease rating scale that could be administered remotely. Parkinsonism Related Disord. 2013 February. 19(2): 218-221.
4. Dorsey R, Deuel L, Voss T, et al. M. Increasing access to specialty care: a pilot, randomized controlled trial of telemedicine for Parkinson's disease. Movement Disorder. 2010: 25(11), 1652-1659.
5. Ben-Pazi H, Browne P, Chan P, et al. The promise of telemedicine for movement disorders: an interdisciplinary approach. Current neurology and neuroscience reports. 2018; 18(5): 1-10.
6. Wilkinson J, Spindler M, Wood S, et al. High patient satisfaction with telehealth in Parkinson disease: a randomized controlled study. Neurology: Clinical Practice. 2016; 6(3): 241-251.
7. Dorsey ER, Okun MS, Bloem BR (2020) Care, Convenience, Comfort, Confidentiality, and Contagion: The 5 C's that Will Shape the Future of Telemedicine. J Parkinsons Dis 10(3):893-897.
8. Bloem BR, Dorsey RE, Okun M (2020) The coronavirus disease 2019 Crisis as Catalyst for Telemedicine for Chronic Neurological Disorders. JAMA Neurology 77(8), 927-928.
9. A, Papa SM, Brundin P, Fung VSC, et al (2020) Impact of the COVID-19 Pandemic on Parkinson's Disease and Movement Disorders. Mov Disord Clin Pract 7(4):357-360.
10. Cubo E, Hassan A, Bloem BR, Mari Z, Group MD-TS (2020) Implementation of Telemedicine for Urgent and Ongoing Healthcare for Patients with Parkinson's Disease During the COVID-19 Pandemic: New Expectations for the Future. J Parkinsons Dis 10(3), 911-913.
11. Grossman et al. Rapid implementation of virtual neurology in response to the COVID-19 pandemic. Neurology 2020; 94:1077-1087.
12. Hassan A, Mari Z, Gatto EM, et al. Global Survey on Telemedicine Utilization for Movement Disorders During the COVID-19 Pandemic. Mov Disord. 2020;35(10):1701-1711.
13. Larson D, Schneider R and Simuni T. A new era: the growth of video-based visits for remote management of persons with Parkinson’s disease. Journal of Parkinson’s disease 2021; 11(s1):S27-S34.
14. Nicholas S Caron, PhD, Galen EB Wright, PhD, and Michael R Hayden. Huntington’s disease. Gene Reviews. October 23, 1998; Last Update: June 11, 2020.
15. HDSA Centers of Excellence. https://hdsa.org/find-help/clinical-care-services/hdsa-centers-of-excellence
16. Bull MT, Darwin K, Venkataraman V, Wagner J, Beck CA, Dorsey ER, et al. A pilot study of virtual visits in Huntington disease. J Huntingtons Dis. 2014;3:189–95. 23. Hawkins AK,
17. Creighton S, Ho A, McManus B, Hayden MR. Providing predictive testing for Huntington disease via telehealth: results of a pilot study in British Columbia, Canada. Clin Genet. 2013;84:60–4.
18. D Trundell, G Palermo, S Schobel, J Long, B Leavitt, S Tabrizi. Defining clinically meaningful change on the composite unified Huntington’s disease rating scale (cUHRS). Neurology April 2019. 92(15) P1.8-043
19. Mestra, MK Forjaz, M Philipp, Cardoso F, Ferreira J, Reilmann R, C Sampaio, C Goetz, E Cubo, P Martinez-Martin, G Stebbins. Rating scales for motor symptoms and signs in Huntington’s disease: Critique and recommendations. Mov Disord Clin Pract. 2018 Mar-Apr; 5(2) 111-117.
20. Klempír, Jirí, et al. "Unified Huntington's disease rating scale: clinical practice and a critical approach." Functional neurology 21.4 (2006): 217.
21. Smith A. Symbol Digit Modalities Test: Manual. Los Angeles: Western Psychological Services; 1982.
22. Golden C and Freshwater SM. The stroop color and word test: a manual for clinical and experimental uses. Wood dale, IL stoelting Co, 2002.
23. A Abdolahi, M Bull, K Darwin, V Venkataramna, M Grana, R Dorsey, K Biglan. A feasibility study of conducting the Montreal Cognitive Assessment remotely in individuals with movement disorders. Health Informatics Journal 2016 22(2) 304-311.
24. Frank S. LBA-18: Utility of the Virtual Unified Huntington’s Disease Rating Scale (vUHDRS®) MDS International Congress 2023
25. Mishra S, Dhuna N, Lancki N, Yeh C, Larson DN. Telehealth utilization and patient satisfaction in an ambulatory movement disorders center during the COVID-19 pandemic. J Telemed Telecare. 2024;30(8):1293-1299.
26. Cubo E, Delgado-López PD. Telemedicine in the Management of Parkinson's Disease: Achievements, Challenges, and Future Perspectives. Brain Sci. 2022;12(12):1735.
27. Srinivasan R, Ben-Pazi H, Dekker M, et al. Telemedicine for Hyperkinetic Movement Disorders. Tremor Other Hyperkinet Mov (N Y). 2020
28. Shalash A, Spindler M, Cubo E. Global Perspective on Telemedicine for Parkinson's Disease. J Parkinsons Dis. 2021